dr. lopes on the keynote-042 results of frontline pembrolizumab in nsclc
Published 6 years ago • 825 plays • Length 2:30Download video MP4
Download video MP3
Similar videos
-
3:19
frontline pd-l1 monotherapy: keynote-042 and impower110
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
1:14
keynote-042: revolutionizing lung cancer treatment with pembrolizumab monotherapy
-
5:00
implications for pembrolizumab in nsclc
-
4:47
benefit of pembrolizumab in nsclc: the keynote trials
-
1:11
dr. lopes on the rationale to stop immunotherapy after 2 years in lung cancer
-
1:54
dr. wakelee on fda approval of frontline pembrolizumab in nsclc
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
1:18
dr. reck on the safety of pembrolizumab in keynote-024 in metastatic nsclc
-
3:31
the keynote-024 precedent for advanced-nsclc treatment
-
2:25
dr. gadgeel on updated keynote-189 data in nsclc
-
11:05
keynote-042: should pembrolizumab replace chemo for broader population with adv. nsclc? (bmic-038)
-
1:48
results of keynote-024 trial of pembrolizumab in nsclc
-
1:00
dr. raez on the keynote-407 trial in squamous cell carcinoma of the lung
-
1:22
updated outcomes of keynote-010 of pembrolizumab for nsclc
-
1:18
dr. joel neal on impact of pd-l1 tests on pembrolizumab, nivolumab efficacy in frontline nsclc
-
8:19
keynote trial data: pembrolizumab’s role in nsclc
-
4:16
upfront pd-1 inhibitor monotherapy in advanced nsclc
-
3:47
pembrolizumab as treatment for oligometastatic nsclc